Tropical infectious diseases in human immunodeficiency virus-infected patients

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 947-965

  Karp, Christopher L ^a   Neva, Franklin A ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; AZITHROMYCIN; BENZNIDAZOLE; CD28 ANTIGEN; CD4 ANTIGEN; CHLOROQUINE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; FANSIDAR; FLUCONAZOLE; GAMMA INTERFERON; IMMUNOGLOBULIN; ISONIAZID; ITRACONAZOLE; JAPANESE ENCEPHALITIS VACCINE; LINDANE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; NIFURTIMOX; PNEUMOCOCCUS VACCINE; QUININE; RIBAVIRIN; RIFAMPICIN; SULFONAMIDE; UNINDEXED DRUG; YELLOW FEVER VACCINE;

AMEBIASIS; BABESIOSIS; DIARRHEA; EHRLICHIOSIS; EPIDEMIC ENCEPHALITIS; HISTOPLASMA CAPSULATUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEPROSY; MALARIA; MEASLES; MYCOSIS; NEUROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PARACOCCIDIOIDES BRASILIENSIS; PENICILLIUM MARNEFFEI; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RICKETTSIOSIS; SCABIES; SPOROTHRIX SCHENCKII; STRONGYLOIDIASIS; TOPICAL DRUG ADMINISTRATION; TRYPANOSOMIASIS; TUBERCULOSIS; VISCERAL LEISHMANIASIS; YELLOW FEVER;

EID: 0032959674     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514745     Document Type: Review

References (120)

1. 1. Morrow RH, Colebunders RL, Chin J. Interactions of HIV infection with endemic tropical diseases. AIDS 1989;3:S79-87.
2. 2. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. Clin Infect Dis 1995;21: S1-11.
3. 3. Kaplan JE, Hu DJ, Holmes KK, et al. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996;55:1-11.
4. 4. Fleming AF. Opportunistic infections in AIDS in developed and developing countries. Trans R Soc Trop Med Hyg 1990;84:S1-6.
5. 5. Gilks CF. The clinical challenge of the HIV epidemic in the developing world. Lancet 1993;342:1037-9.
6. 6. Roederer M, Raju PA, Mitra DK, Herzenberg LA. HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J Clin Invest 1997; 99:1555-64.
7. 7. Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci USA 1993:90:948-52.
8. 8. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575-81.
9. 9. Clerici M, Sarin A, Coffman RL, et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA 1994;91: 11811-5.
10. 10. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 1994;264:244-8.
11. 11. Greenberg AE, Nguyen-Dinh P, Mann JM, et al. The association between malaria, blood transfusions, and HIV seropositivity in a pediatric population in Kinshasa, Zaire. JAMA 1988;259:545-9.
12. 12. Feldmeier H, Krantz I, Poggensee G. Female genital schistosomiasis as a risk-factor for the transmission of HIV. Int J STD AIDS 1994;5: 368-72.
13. 13. DiNubile MJ. Reliving a nightmare: a hard (and tragic) lesson in humility. Clin Infect Dis 1996;23:160-4.
14. 14. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997;25:S299-312.
15. 15. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1997;25:S313-35.
16. 16. Anglaret X, Diagbouga S, Mortier E, et al. CD4+ T-lymphocyte counts in HIV infection: are European standards applicable to African patients? J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:361-7.
17. 17. Vandenbruaene M, Colebunders R, Goeman J, et al. Evaluation of two staging systems for HIV infection for use in developing countries. AIDS 1993;7:1613-5.
18. 18. McGregor IA. Epidemiology, malaria and pregnancy. Am J Trop Med Hyg 1984;33:517-25.
19. 19. Steketee RW, Wirima JJ, Bloland PB, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996;55:42-9.
20. 20. Bloland PB, Wirima JJ, Steketee RW, et al. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 1995;9:721-6.
21. 21. Fansidar-associated fatal reaction in an HIV-infected man. MMWR Morb Mortal Wkly Rep 1988;37:571-3.
22. 22. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency infection. Am J Trop Med Hyg 1998;59:813-22.
23. 23. Locksley RM, Louis JA. Immunology of leishmaniasis. Curr Opin Immunol 1992;4:413-8.
24. 24. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986;154:1003-11.
25. 25. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-319.
26. 26. Alvar J. Leishmaniasis and AIDS co-infection. The Spanish example. Parasitology Today 1994;10:160-3.
27. 27. Gramiccia M, Gradoni L, Troiani M. Heterogeneity among zymodemes of Leishmania infantum from HIV-positive patients with visceral leishmaniasis in south Italy. FEMS Microbiol Lett 1995;128:33-8.
28. 28. Medrano FJ, Jimenez-Mejias E, Calderon C, et al. An easy and quick method for the diagnosis of visceral leishmaniasis in HIV-1 infected individuals [letter]. AIDS 1993;13:1399.
29. 29. Molina R, Canavate C, Cercenado E, Laguna F, Lopez-Velez R, Alvar J. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus. AIDS 1994;8: 277-9.
30. 30. Piarroux R, Gambarelli F, Dumon H, et al. Comparison of PCR with direct examination of bone marrow aspiration, mycloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J Clin Microbiol 1994;32:746-9.
31. 31. Gradoni L, Scalone A, Gramiccia M. HIV-Leishmania coinfections in Italy: serological data as an indication of the sequence of the two infections. Trans R Soc Trop Med Hyg 1993;87:94-6.
32. 32. de Gorgolas M, Castrillo JM, Fernandez Guerrero ML. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma. Clin Infect Dis 1993;17:56-8.
33. 33. Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg 1993;48:666-9.
34. 34. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344:1599-600.
35. 35. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, Davidson R. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995; 21:188-93.
36. 36. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994;87:75-81.
37. 37. Gillis D, Klaus S, Schnur LF, et al. Diffusely disseminated cutaneous Leishmania major. Pediatr Infect Dis J 1995;14:247-9.
38. 38. Hernandez DE, Oliver M, Martinez C, Planas G. Visceral leishmaniasis with cutaneous and rectal dissemination due to L. braziliensis in acquired immunodeficiency syndrome (AIDS). Int J Dermatol 1995;34: 114-5.
39. 39. Machado ES, Braga M, da Cruz AM, et al. Disseminated American mucocutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report. Mem Inst Oswaldo Cruz 1992;87:487-92.
40. 40. Nogueira-Castañon MCM, Pereira CAC, Fustado T. Unusual association of American cutaneous leishmaniasis and acquired immunodeficiency syndrome. Int J Dermatol 1996;35:295-7.
41. 41. Hernandez D, Rodriguez N, Martinez C, Garcia L, Convit J. Leishmania braziliensis causing visceral leishmaniasis in a patient with human immunodeficiency virus infection, identified with the aid of the polymerase chain reaction. Trans R Soc Trop Med Hyg 1993;87:627-8.
42. 42. Hoff R, Teixeira RS, Carvalho JS, Mott KE. Trypanosoma cruzi in the cerebrospinal fluid during the acute stage of Chagas' disease. N Engl J Med 1978;298:604-6.
43. 43. Rocha A, de Meneses ACO, Moreira A, et al. Pathology of patients with Chagas' disease and AIDS. Am J Trop Med Hyg 1994;50:261-8.
44. 44. Ferreira MS, Nishioka SA, Silvestre MT, Borges AS, Nunes-Araujo FR, Rocha A. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis 1997;25:1397-400.
45. 45. Di Lorenzo GA, Pagano MA, Taratuto AL, et al. Chagas' granulomatous encephalitis in immunosuppressed patients: computed tomography and magnetic resonance imaging findings. J Neuroimaging 1996;6:94-7.
46. 46. Nishioka SA, Ferreira MS, Rocha A, et al. Reactivation of Chagas' disease successfully treated with benznidazole in a patient with AIDS. Mem Inst Oswaldo Cruz 1993;88:493-6.
47. 47. Solari A, Saavedra H, Sepulveda C, et al. Successful treatment of Trypanosoma cruzi encephalitis in a patient with hemophilia and AIDS. Clin Infect Dis 1993;16:255-9.
48. 48. Sison JP, Kemper CA, Loveless M, et al. Disseminated Acanthamoeba infection in patients with AIDS: case reports and review. Clin Infect Dis 1995;20:1207-16.
49. 49. Bartlett JG. Medical management of HIV infection. Baltimore: Port City Press, 1998 (available at: http://www.hopkins-aids.edu/).
50. 50. Cohen PT, Sande MA, Volberding PA. The AIDS knowledge base: a textbook on HIV disease From the University of California, San Francisco, and the San Francisco General Hospital, 3rd ed. Boston: Little, Brown and Company, 1998 (available at: http://hivsite.uesf.edu/).
51. 51. Cohen AJ, Steigbigel RT. Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis 1996;174:615-8.
52. 52. Skiest DJ, Keiser P. Clinical significance of eosinophilia in HIV-infected individuals. Am J Med 1997;102:449-53.
53. 53. Genta RM. Dysregulation of strongyloidiasis: a new hypothesis. Clin Microbiol Rev 1992;5:345-55.
54. 54. Pelletier LI. Jr. Chronic strongyloidiasis in World War II Far East exprisoners of war. Am J Trop Med Hyg 1984;33:55-61.
55. 55. Igra-Siegman Y, Kapila R, Sen P, Kaminski ZC, Louria DB. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 1981; 3:397-407.
56. 56. Update on acquired immune deficiency syndrome (AIDS) - United States. MMWR Morb Mortal Wkly Rep 1982;31:507-8, 513-4.
57. 57. Phillips SC, Mildvan D, William DC, Gelb AM, White MC. Sexual transmission of enteric protozoa and helminths in a venereal disease clinic population. N Engl J Med 1981;305:603-6.
58. 58. Petithory JC, Derouin F. AIDS and strongyloidiasis in Africa. Lancet 1987;1:921.
59. 59. Neto VA, Pasternak J, Moreira AA, Duarte MI, Campos R, Braz LM. Strongyloides stercoralis hyperinfection in the acquired immunodeficiency syndrome. Am J Med 1989;87:602-3.
60. 60. Tarimo DS, Killewo JZ, Minjas JN, Msamanga GI. Prevalence of intestinal parasites in adult patients with enteropathic AIDS in north-eastern Tanzania. East Afr Med J 1996;73:397-9.
61. 61. Lindo JF, Dubon JM, Ager AL, et al. Intestinal parasitic infections in human immunodeficiency virus (HIV)-positive and HIV-negative individuals in San Pedro Sula, Honduras. Am J Trop Med Hyg 1998;58: 431-5.
62. 62. Marsh BJ. Infectious complications of human T cell leukemia/lymphoma virus type I infection. Clin Infect Dis 1996;23:138-45.
63. 63. Santamaría-Fríes M, Fajardo LF, Sogin ML, et al. Lethal infection by a previously unrecognized metazoan parasite. Lancet 1996;347: 1797-801.
64. 64. Connor DH, Sparks AK, Strano AJ, Neafie RC, Juvelier B. Disseminated parasitosis in an immunosuppressed patient. Arch Pathol Lab Med 1976;100:65-8.
65. 65. Chermette R, Bussiéras J, Marionneau J, et al. Cysticercose envahissante a Taenia crassiceps chez un patient atteint de sida. Bull Acad Natl Med 1995;4:777-83.
66. 66. Francois A, Favennec L, Cambon-Michot C, et al. Taenia crassiceps invasive cysticereosis: a new human pathogen in acquired immunodeficiency syndrome? Am J Surg Pathol 1998;22:488-92.
67. 67. Klinker H, Tintelnot K, Joeres R, et al. Taenia-crassiceps-infection bei AIDS. Dtsch Med Wochenschr 1992;117:133-8.
68. 68. Sailer M, Boelder B, Allerberger F, et al. Alveolar echinococcosis of the liver in a six-year-old girl with acquired immunodeficiency syndrome. J Pediatr 1997;130:320-3.
69. 69. Karanja DM, Boyer AE, Strand M, et al. Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1. Am J Trop Med Hyg 1998;59:307-11.
70. 70. Karanja DMS, Colley DG, Nahlen BL, et al. Studies on schistosomiasis in western Kenya. I. Evidence for immune-facilitated excretion of schistosome eggs from patients with Schistosoma mansoni and HIV collections. Am J Trop Med Hyg 1997;56:515-21.
71. 71. Schlesinger I, Oelrich DM, Tyring SK. Crusted (Norwegian) scabies in patients with AIDS: the range of clincial presentations. South Med J 1994;87:352-6.
72. 72. Glover A, Young L, Goltz AW. Norwegian scabies in AIDS: report of a case resulting in death from associated sepsis. J Am Acad Dermatol 1987;16:396-8.
73. 73. Solomon BA, Haut SR, Carr EM, Shalita AR. Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem. J Fam Pract 1995;30:291-6.
74. 74. Supparatpinyo K, Khamwan C, Vaosoung V, et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994;344:110-3.
75. 75. Phillips P. Penicillium marneffei part of Southeast Asian AIDS. JAMA 1996;276:86-7.
76. 76. Chariyalertsak S, Sirisanthana T, Supparatpinyo K, Nelson KE. Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir? J Infect Dis 1996;173:1490-3.
77. 77. Chariyalertsak S, Sirisanthana T, Supparatpinyo K, Praparattanapan J, Nelson KE. Case control study of risk factors for Penicillium marneffei infection in HIV-infected patients in northern Thailand. Clin Infect Dis 1997;24:1080-6.
78. 78. Kantipong P, Panich V, Pongsurachet V, Watt G. Hepatic penicilliosis in patients without skin lesions. Clin Infect Dis 1998;26:1215-7.
79. 79. Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997;24:1169-71.
80. 80. Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;26:1107-10.
81. 81. Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993;37:2407-11.
82. 82. Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996;23:125-30.
83. 83. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A randomized, double-blind, placebo-controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with human immunodeficiency virus. N Engl J Med 1998;339:1739-43.
84. 84. Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993;6:89-117.
85. 85. Goldani LZ, Sugar AM. Paracoccidioidomycosis and AIDS: an overview. Clin Infect Dis 1995;21:1275-81.
86. 86. Nishioka SA. Paracoccidioidomycosis and AIDS [letter]. Clin Infect Dis 1996;22:1132-3.
87. 87. Carme B, Ngolet A, Ebikili B, Ngaporo AI. Is African histoplasmosis an opportunistic fungal infection in AIDS? Trans R Soc Trop Med Hyg 1990;84:293.
88. 88. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteria in HIV-positive patients. J Infect Dis 1992;165:1082-5.
89. 89. Lucas S. Human immunodeficiency virus and leprosy. Lepr Rev 1993; 64:97-103.
90. 90. Delaporte E, Alfandari S, Piette F. Mycobacterium ulcerans associated with infection due to the human immunodeficiency virus. Clin Infect Dis 1994;18:839.
91. 91. Kantipong P, Watt G, Jongsakul K, Choenchitra C. Infection with human immunodeficiency virus does not influence the clinical severity of scrub typhus. Clin Infect Dis 1996;23:1168-70.
92. 92. Uhaa IJ, Maclean JD, Breene CR, Fishbein DB. A case of human ehrlichiosis acquired in Mali: clinical and laboratory findings. Am J Trop Med Hyg 1992;46:161-4.
93. 93. Fichtenbaum CJ, Peterson LR, Weid GJ. Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome. Am J Med 1993;95:351-7.
94. 94. Barenfanger J, Patel PG, Dumler JS, Walker DH. Identifying human ehrlichiosis. Lab Med 1996;27:372-4.
95. 95. Paddock CD, Suchard DP, Grumbach KL. Fatal seronegative ehrlichiosis in a patient with HIV infection. N Engl J Med 1993;329:1164-7.
96. 96. Tanphaichitra D. Tropical disease in the immunocompromised host: melioidosis and pythiosis. Rev Infect Dis 1989;11:S1629-42.
97. 97. Kipp W, Kamugisha J, Rehle T. Meningococcal meningitis and HIV infection: results from a case-control study in western Uganda. AIDS 1992;6:1557-8.
98. 98. Okhuysen PC, Crane JK, Pappas J. St. Louis encephalitis in patients with human immunodeficiency virus infection. Clin Infect Dis 1993;17: 140-1.
99. 99. Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1997;16:1177-9.
100. 100. WHO EPI. Available at: http://www.who.int/gpv-dvace/service/policy.htm (and) http://wvvw.who.int/gpv-dvace/diseases/HIV.htm. Accessed 9 February 1999.
101. 101. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 1993;42:1-18.
102. 102. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45: 1-35.
103. 103. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989;216: 2512-6.
104. 104. Palumbo P, Hoyt L, Demasio K, et al. Population-based study of measles and measles immunization in HIV-infected children. Pediatr Infect Dis J 1992;11:1008-14.
105. 105. Measles prevention. MMWR Morb Mortal Wkly Rep 1989;38(suppl 9): 1-18.
106. 106. Brunell PA, Vimal V, Sandhu M, et al. Abnormalities of measles antibody response in HIV type 1 (HIV-1) infection. J AIDS Hum Retrovirol 1995;10:540-8.
107. 107. Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis 1992;165:262-7.
108. 108. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996;45:603-6.
109. 109. Oshitani H, Suzuki H, Mpabalwani ME, et al. Measles case fatality by sex, vaccination status, and HIV-1 antibody in Zambian children [letter]. Lancet 1996;348:415.
110. 110. Oshitani H, Mpabalwani M, Kasolo F, et al. Measles infection in hospitalized children in Lusaka, Zambia. Ann Trop Pediatr 1995;15:167-72.
111. 111. Adle Biassette H, Bourhy H, Gisselbrecht M, et al. Rabies encephalitis in a patient with AIDS: a clinicopathological study. Acta Neuropathol 1996;92:415-20.
112. 112. Bodsworth NJ, Neilsen GA, Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1 year follow-up. AIDS 1997;11:747-9.
113. 113. Neilscn GA, Bodsworth NJ, Watts N. Influence of HIV infection on response to a novel whole virion hapatilis A vaccine in homosexual men (abstract no A3044). In: Program and abstracts of the XI International Conference on AIDS (Vancouver, British Columbia, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
114. 114. Colebunders R, Mann JM, Francis H, et al. Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection. J Infect Dis 1988;157:314-8.
115. 115. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993;54:26-36.
116. 116. Oshitani H, Kasolo FC, Mpabalwani M, et al. Association of rotavirus and human immunodeficiency virus infection in children with acute diarrhea, Lusaka, Zambia. J Infect Dis 1994;169:897-900.
117. 117. Kemper CA, Linett A, Kane C, Deresinski SC. Travels with HIV: the compliance and health of HIV-infected adults who travel. Int J STD AIDS 1997;8:44-9.
118. 118. von Reyn CF, Mann JM, Chin J. International travel and HIV infection. Bull WHO 1990;68:251-9.
119. 119. Wilson ME, von Reyn F, Fineberg HV. Infections in HIV-infected travelers: risks and prevention. Ann Intern Med 1991;114:582-92.
120. 120. Gostin LO, Cleary PD, Mayer KH, Brandt AM, Chittenden FH. Screening immigrants and international travelers for the human immunodeficiency virus. N Engl J Med 1990;322:1743-6.